Lenalidomide Teva

What Is Lenalidomide Teva and What Is It Used For?

Quick Answer: Lenalidomide Teva is a generic immunomodulatory drug (IMiD) containing lenalidomide. It is primarily used to treat multiple myeloma, myelodysplastic syndromes with deletion 5q, mantle cell lymphoma, and follicular lymphoma. It works by modulating the immune system, directly killing cancer cells, and inhibiting angiogenesis.

Lenalidomide Teva belongs to a class of medications known as immunomodulatory drugs (IMiDs). It is a structural analogue of thalidomide but with a significantly improved efficacy and safety profile. The active ingredient, lenalidomide, was first approved by the U.S. Food and Drug Administration (FDA) in 2005 and subsequently by the European Medicines Agency (EMA) in 2007. Lenalidomide Teva is a generic version, meaning it contains the same active substance as the originator product (Revlimid) and has been demonstrated to be bioequivalent through rigorous regulatory evaluation.

The mechanism of action of lenalidomide is multifaceted. At the molecular level, lenalidomide binds to cereblon (CRBN), a substrate receptor of the cullin-RING E3 ubiquitin ligase complex CRL4^CRBN. This binding alters the substrate specificity of the ligase, leading to the ubiquitination and subsequent proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). The degradation of these zinc-finger proteins is critical for the anti-myeloma activity of lenalidomide, as IKZF1 and IKZF3 are essential transcription factors for myeloma cell survival and proliferation. Additionally, lenalidomide stimulates T-cell proliferation and interleukin-2 (IL-2) production, enhances natural killer (NK) cell cytotoxicity, and inhibits pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6).

Lenalidomide Teva is approved for several clinical indications:

• Multiple Myeloma (newly diagnosed): In combination with dexamethasone in adult patients who are not eligible for autologous stem cell transplantation (ASCT), or as maintenance therapy following ASCT.
• Multiple Myeloma (relapsed/refractory): In combination with dexamethasone in adult patients who have received at least one prior therapy.
• Myelodysplastic Syndromes (MDS): For treatment of transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality, when other therapeutic options are insufficient or inadequate.
• Mantle Cell Lymphoma (MCL): As monotherapy for adult patients whose disease has relapsed or progressed after at least two prior therapies, one of which included bortezomib.
• Follicular Lymphoma (FL): In combination with rituximab for previously treated adult patients.

The introduction of lenalidomide has been transformative in the treatment of multiple myeloma. Clinical trials, including the landmark FIRST trial (Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide), demonstrated that continuous lenalidomide plus dexamethasone significantly improved progression-free survival compared to the prior standard of melphalan-prednisone-thalidomide in transplant-ineligible patients. Similarly, the CALGB 100104 and IFM 2005-02 trials established lenalidomide maintenance after ASCT as a standard of care, showing significant improvements in both progression-free and overall survival.

What Should You Know Before Taking Lenalidomide Teva?

Quick Answer: Before starting lenalidomide, you must undergo a pregnancy test (if applicable), blood count assessment, and evaluation for thromboembolism risk. This medication is absolutely contraindicated in pregnancy and requires strict adherence to a pregnancy prevention programme. Patients must not donate blood during treatment or for at least 7 days after stopping.

Contraindications

Lenalidomide Teva must not be used in the following situations:

• Pregnancy: Lenalidomide is a known human teratogen. It must never be used during pregnancy. Exposure during the first trimester can cause severe, life-threatening birth defects including phocomelia (limb malformations), congenital heart defects, renal abnormalities, and other organ malformations. Even a single dose during pregnancy can cause harm.
• Women of childbearing potential who are unable or unwilling to comply with the mandatory pregnancy prevention programme, including the use of at least one highly effective method of contraception for at least 4 weeks before treatment, during treatment, and for at least 4 weeks after treatment cessation.
• Hypersensitivity to the active substance lenalidomide or to any of the excipients in the capsule formulation.

Warnings and Precautions

Your healthcare provider will monitor you closely throughout treatment with lenalidomide. Several important safety considerations apply:

Haematological toxicity: Neutropenia and thrombocytopenia are the most common dose-limiting toxicities of lenalidomide. Complete blood counts must be monitored weekly for the first 8 weeks of treatment and then monthly thereafter, or as clinically indicated. Dose modifications, including interruption and reduction, may be necessary depending on the severity and duration of cytopenias. Growth factor support (e.g., granulocyte colony-stimulating factor, G-CSF) may be considered for persistent neutropenia.

Venous and arterial thromboembolism: Lenalidomide increases the risk of venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly when used in combination with dexamethasone. The incidence of DVT/PE in clinical trials ranged from 3% to 15%, depending on the combination regimen and patient population. Thromboprophylaxis with aspirin, low-molecular-weight heparin (LMWH), or warfarin is recommended based on individual patient risk assessment. Arterial thrombotic events, including myocardial infarction and stroke, have also been reported.

Second primary malignancies (SPM): An increased incidence of second primary malignancies has been observed in patients treated with lenalidomide, particularly in the maintenance setting after ASCT. These include haematological malignancies (such as acute myeloid leukaemia, AML, and myelodysplastic syndromes) and solid tumours. The benefit-risk balance should be carefully considered before initiating lenalidomide therapy. Physicians should screen patients for the development of SPMs using standard cancer screening methods.

Hepatotoxicity: Hepatic failure, including fatal cases, has been reported in patients treated with lenalidomide in combination with dexamethasone. Liver function should be monitored regularly, and treatment should be interrupted or discontinued if clinically significant elevations in liver enzymes occur.

Tumour lysis syndrome (TLS): Patients with a high tumour burden may be at risk of TLS when initiating lenalidomide. Appropriate prophylactic measures, including adequate hydration and monitoring of electrolytes and renal function, should be implemented.

Infections: Lenalidomide can suppress the immune system and increase susceptibility to infections, including serious and sometimes fatal bacterial, viral, and fungal infections. Patients should be monitored for signs and symptoms of infection and treated promptly. Consideration should be given to antiviral prophylaxis, particularly for herpes zoster reactivation.

Pregnancy and Breastfeeding

Pregnancy: Lenalidomide is absolutely contraindicated during pregnancy. The pregnancy prevention programme (PPP) requires all patients to meet specific conditions before, during, and after treatment:

• Women of childbearing potential must have two negative pregnancy tests (sensitivity of at least 25 mIU/mL) before starting treatment — the first test within 10–14 days before the prescription, and the second within 24 hours before the prescription.
• Pregnancy tests must be repeated every 4 weeks during treatment and 4 weeks after treatment completion.
• At least one highly effective contraceptive method must be used for at least 4 weeks before, during, and for at least 4 weeks after treatment cessation.
• Male patients must use condoms during treatment and for at least 7 days after dose interruptions and/or cessation if their partner is of childbearing potential or pregnant.

Breastfeeding: It is not known whether lenalidomide is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding must be discontinued during treatment with lenalidomide and for at least 7 days after the last dose.

Fertility: In animal studies, lenalidomide showed no adverse effects on fertility. However, given its teratogenic potential, fertility planning must be carefully managed in consultation with the treating physician.

How Does Lenalidomide Teva Interact with Other Drugs?

Quick Answer: Lenalidomide has relatively few pharmacokinetic drug interactions since it is minimally metabolised by the liver. However, clinically significant interactions can occur with drugs that increase thromboembolism risk, erythropoiesis-stimulating agents, digoxin, and certain vaccines. Combined use with dexamethasone requires specific monitoring.

Lenalidomide is primarily eliminated renally as unchanged drug, with approximately two-thirds of the dose excreted in urine within 24 hours. Unlike many oncology drugs, lenalidomide undergoes minimal hepatic metabolism and does not significantly interact with cytochrome P450 (CYP) enzymes. This favourable pharmacokinetic profile reduces the potential for classic drug-drug interactions, but several clinically relevant interactions still require attention.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Lenalidomide Teva?

Quick Answer: The dose of lenalidomide varies by indication and ranges from 5 mg to 25 mg daily, typically taken orally on specific days of a 28-day treatment cycle. The dose must be adjusted based on renal function and haematological parameters. Lenalidomide must only be prescribed by physicians experienced in the use of anti-cancer therapies.

Lenalidomide is taken orally, with capsules swallowed whole with water, at approximately the same time each day. Capsules should not be opened, broken, or chewed. The exact dosing regimen depends on the clinical indication, combination partners, and individual patient factors including renal function and blood counts.

Adults

Children

Lenalidomide is not approved for use in children and adolescents under 18 years of age. There are currently no established paediatric indications. The safety and efficacy of lenalidomide in the paediatric population have not been determined, and its use in this age group is not recommended outside of clinical trials supervised by specialist paediatric oncology centres.

Elderly

No specific dose adjustment is required based on age alone. However, elderly patients (aged 75 years and above) are more likely to have reduced renal function, and dose adjustments based on creatinine clearance are essential. Elderly patients are also at higher risk for serious adverse effects, particularly haematological toxicity and thromboembolic events. The FIRST trial demonstrated that patients aged 75 years and older benefited from a reduced starting dose of dexamethasone (20 mg weekly rather than 40 mg) in combination with lenalidomide. Careful monitoring and proactive dose modifications are recommended in this population.

Missed Dose

If a dose of lenalidomide is missed and it has been fewer than 12 hours since the scheduled time, the patient should take the dose as soon as they remember. If more than 12 hours have passed since the regular dosing time, the missed dose should be skipped and the next dose taken at the usual scheduled time. Patients should not take two doses at the same time to compensate for a missed dose. All missed doses should be reported to the treating physician, as frequent omissions may affect treatment efficacy.

Overdose

There is no specific antidote for lenalidomide overdose. In clinical trials, healthy volunteers who received single doses up to 400 mg experienced no significant acute toxicity. In the event of an overdose, supportive care is recommended, including monitoring of haematological parameters and management of any symptoms that arise. Given that lenalidomide is partly removed by dialysis, haemodialysis may be considered in severe cases, although clinical data on this approach are limited. Patients who suspect an overdose should contact their healthcare provider or a poison control centre immediately.

What Are the Side Effects of Lenalidomide Teva?

Quick Answer: The most common side effects of lenalidomide include neutropenia, thrombocytopenia, anaemia, fatigue, diarrhoea, constipation, muscle cramps, and rash. Serious side effects include venous thromboembolism, severe infections, and second primary malignancies. Regular blood monitoring is essential throughout treatment.

Like all medicines, lenalidomide can cause side effects, although not everybody experiences them. The frequency and severity of side effects may vary depending on the indication, dose, combination therapy, and duration of treatment. Haematological side effects are generally the most common and clinically significant. Below is a comprehensive overview of reported side effects organised by frequency according to MedDRA (Medical Dictionary for Regulatory Activities) classifications.

How Should You Store Lenalidomide Teva?

Quick Answer: Store Lenalidomide Teva capsules below 30°C in the original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiry date. Unused or expired capsules must be returned to the pharmacy for safe disposal.

Proper storage of lenalidomide is essential to maintain the drug's stability, efficacy, and safety. The capsules should be stored in their original blister packaging until ready for use. Do not remove capsules from the blister pack until immediately before taking them. Store at a temperature not exceeding 30°C (86°F). No special storage conditions regarding refrigeration are required.

Given the teratogenic nature of lenalidomide, particular care must be taken to ensure that the medication is kept in a secure location out of the reach of children, pregnant women, and anyone not prescribed the medication. Capsules should not be opened, crushed, or handled by anyone other than the patient for whom they are prescribed. If a capsule is accidentally broken or the powder is spilled, the area should be cleaned immediately and hands washed thoroughly.

Do not use Lenalidomide Teva after the expiry date printed on the carton and blister pack. The expiry date refers to the last day of that month. Any unused capsules or expired medication should not be disposed of via household waste or wastewater. Return unused medication to a pharmacy for appropriate disposal in accordance with local regulations. This is particularly important for lenalidomide to prevent accidental exposure of others, especially pregnant women.

What Does Lenalidomide Teva Contain?

Quick Answer: Each Lenalidomide Teva hard capsule contains the active ingredient lenalidomide (available in strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, and 25 mg). The capsules also contain inactive ingredients including lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

Active ingredient: Lenalidomide. The amount of active ingredient varies depending on the capsule strength. The 2.5 mg capsule contains 2.5 mg of lenalidomide, and other strengths contain proportionally higher amounts up to 25 mg.

Inactive ingredients (excipients): The capsule contents typically include:

• Lactose monohydrate — a filler used to give the capsule content adequate volume. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
• Microcrystalline cellulose — a bulking and binding agent that helps form the capsule contents.
• Croscarmellose sodium — a disintegrant that helps the capsule contents break apart in the gastrointestinal tract for proper absorption.
• Magnesium stearate — a lubricant used in the manufacturing process.

Capsule shell: The hard capsule shell is composed of gelatin and titanium dioxide (E171). Different strengths may have different coloured capsules using additional colourants such as iron oxide yellow (E172), iron oxide red (E172), indigo carmine (E132), or iron oxide black (E172) to facilitate identification of the correct strength.

Printing ink: The capsule markings are applied using a pharmaceutical-grade printing ink containing shellac, propylene glycol, potassium hydroxide, and iron oxide black (E172).

References

This article is based on the following peer-reviewed sources and international guidelines:

1. European Medicines Agency (EMA). Lenalidomide — Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Accessed January 2026.
2. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917. doi:10.1056/NEJMoa1402551 (FIRST trial).
3. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. doi:10.1200/JCO.2017.72.6679.
4. Dimopoulos MA, Swern AS, Li JS, et al. Efficacy and safety of lenalidomide in combination with dexamethasone in relapsed/refractory multiple myeloma: pooled analysis of MM-009 and MM-010 studies. Leukemia. 2009;23(11):2147–2152.
5. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465. doi:10.1056/NEJMoa061292.
6. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 3.2025. Available at: www.nccn.org.
7. European Society for Medical Oncology (ESMO). Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322.
8. U.S. Food and Drug Administration (FDA). Lenalidomide prescribing information. Available at: www.accessdata.fda.gov.
9. World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. Geneva: World Health Organization; 2023.
10. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305. doi:10.1126/science.1244851.

Medical Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and clinical pharmacologists with expertise in oncology, haematology, and pharmacotherapy.

Our Qualifications

• Board certification in oncology, haematology, and/or clinical pharmacology
• Published in peer-reviewed medical journals including New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology
• Continuing medical education in the latest clinical trial data and regulatory updates
• Adherence to the GRADE evidence framework for all recommendations

Editorial Standards

Transparency statement: iMedic receives no funding from pharmaceutical companies. All content is editorially independent. Our editorial team has no conflicts of interest related to the medications described. For questions about our editorial process, contact us at our contact page.